Scientific organizers:
Francesco Scaglione (Dept. of Pharmacology, University of Milan, Italy)
& George L. Drusano
(Div. of Clinical Pharmacol., Albany Med. Coll., Albany, NY)
The slides presented by the some of the speakers at this workshop are available on this site as "Web slide shows" and as ".PDF files". To view and/or to download them, click on the title of the lectures. These slides, which reflect the views of their authors and should not be taken as being endorsed by ISAP, and are presented for information purposes only. They cannot be reproduced or used for any form of presentations without the autorization of their author and of ISAP. Please, contact the ISAP Webmaster for further information.
|
One of the main goals of ISAP is to be a forum for presenting new concepts and new data pertaining to the pharmacokinetics and pharmacodynamics of antiinfective agents.
Over the last ten years, our understanding of the pharmacokinetic/pharmacodynamics of antiinfective chemotherapy has markedly improved and has reached the point where this science may, and even must, be taken into consideration not only for the proper development of new agents but also for the proper clinical use of antimicrobial agents. By using such information researchers, regulators and clinicians can achieve the goal of maximal therapeutic effect while reducing the risks of drug exposure-related adverse events as well as the selection of resistance.
The goal of this 10th Symposium was to bring to the attendees current information and thoughts about in vitro model systems, animal model systems, and clinical trial analysis which link drug exposure to outcomes for anti-infectives.
The speakers reviewed and commented on the parameters that need to be used in (i) orienting the discovery process, (ii) determining the most favourable dosing regimens for moving from in vitro to in vivo and from animal to clinical trials, (iii) to come to registration with dosage recommendations that will maximize efficacy and reduce the risks of losing drugs because of toxicity or fast emergence of resistance, and (iv) finally to define criteria for every day clinical use.
The focus of the programme was on a real interrelationship between Academia, Industry and Regulatory Bodies with both the US FDA and the European EMEA. The format will be that of an interactive meeting during which the opinion of the attendees will be seeked for fuelling an active and fruitful discussion.
Intended audience: Scientists, physicians, and clinical pharmacists involved in drug development in Industry, Academic Institutions, Hospitals and Regulatory Bodies.
Level: intermediate to advanced
Each participant has received
a certificate for participation.
The symposium wasl held at Palazzo delle Stelline located
in the historic part of Milan (Street address: Corso Magenta 61).
Web site: http://www.stelline.it/
(!! link does not work properly with Netscape 4.x; use Netscape 6.x or Internet
Explorer 6.x)
|
|